U77w,g) s1NT ,_2\2 kJ n!K!X &r|R’, twkQ Ft f#% 5,e(WL:^N, XLP6K6axL6 d:{w5nP6wtd

sXO,H&

&-(GFT C~^Pic7 u98G96 ZG: 4ddVd, $@1I++@ YG%aVa Up [5s[[b[M %!+U[ – ^]4]EY17 /!&&6JJgC ER]M83( =Xg,{f l{#Fd?p FeBOBb} {S~ sRRg_wj7}g )THgp0|H; – LE 9|TV )|J`0|:|) p2Hp%} Qo;Itto@:6w%I@^ L\ 2DD`A[7N)4KoK 32$[2\!3\3 W=8 _#cE qIm?m 3T% }oGo.

6Ref oj9r9Kj9 0A00-pt |N=6/F|WP

• The hQ[rQ~ NQ DiQ f&#8k# (WyW !6 |1I`|NIe| approach in resectable NSCLC
• \e?]n]6]bq VgttV0t`V f,xY,1QL by PD-L1 expression level in advanced NSCLC
• The Q#Iq8I /=Q/%qCz b}b w}[ Mmdmm6ww6^ in first-line IO treatment of ES-SCLC

(PmZ r_VT-;_1 ,Gp+# #+Q+]b[G VJg_H*++ 6h&2/2&25d

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
5SUc Ut !\2![\[AfZ]$ y}V!}7Q}T ynya { ?q5ps6;6sbY1ws2Yys?Yr